GLP1 receptor agonist use was not associated with increased risk of thyroid cancer compared with SGLT2 inhibitor use (hazard ratio 1.16, 95% confidence interval 0.65 to 2.05; table 3, efigure 2). This evidence concerns the gene GLP1R and thyroid gland carcinoma.